Absci

Absci

Yahoo Finance • last month

FDA names acting heads of drug and vaccine units to permanent roles

[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House advisor Heidi Overton as the agency's nex... Full story

Yahoo Finance • last month

AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030

AUSTIN, Texas, Sept. 3, 2026 /PRNewswire/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug discovery ma... Full story

Yahoo Finance • 2 months ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 2 months ago

Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million... Full story

Yahoo Finance • 2 months ago

Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment – Has The Bull Case Changed?

Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures,... Full story

Yahoo Finance • 2 months ago

Absci anticipates ABS-201 interim proof of concept data in 2H 2026, while guiding cash runway into 2H 2028

Earnings Call Insights: Absci (ABSI) Q2 2026 MANAGEMENT VIEW * CEO Sean McClain said the company released “positive interim Phase I data” from the HEADLINE trial, adding “the data suggests the study drug was well tolerated with favorab... Full story

Yahoo Finance • 2 months ago

Absci GAAP EPS of -$0.21 misses by $0.01, revenue of $0.3M misses by $0.63M

* Absci press release [https://seekingalpha.com/pr/20615676-absci-reports-business-updates-and-second-quarter-2026-financial-and-operating-results] (ABSI [https://seekingalpha.com/symbol/ABSI]): Q2 GAAP EPS of -$0.21 misses by $0.01. *... Full story

Yahoo Finance • 2 months ago

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and... Full story

Yahoo Finance • 2 months ago

High-flyer healthcare stocks: Ten names with strong momentum, weak valuations

[Heart Health Concept] Eoneren/E+ via Getty Images Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price veloci... Full story

Yahoo Finance • 3 months ago

Cathie Wood's Ark Invest boosts stakes in Tesla, SpaceX, Meta, trimming Figma, Shopify

Cathie Wood’s ARK Invest’s largest purchase during July 20-24 was Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]), with the firm acquiring an additional $52.7M stake after a steep sell-off post weaker-than-expected Q2 earnings report.... Full story

Yahoo Finance • 3 months ago

A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed

Issued on behalf of MindWalk Holdings Corp. (NASDAQ: HYFT) AUSTIN, Texas, July 24, 2026 /PRNewswire/ -- American News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely... Full story

Yahoo Finance • 3 months ago

As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

Issued on behalf of MindWalk Holdings Corp. MindWalk Holdings Corp. (NASDAQ: HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicin... Full story

Yahoo Finance • 4 months ago

Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity Raise - Has The Bull Case Changed?

Earlier this week, Absci Corporation reported encouraging interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into a multi... Full story

Yahoo Finance • 4 months ago

Absci, FuelCell Energy surge premarket; Cerebras, FedEx tumble

Investing.com - U.S. stock index futures were mixed on Wednesday, with the S&P 500 and Nasdaq edging higher after a bruising two-day selloff in technology and semiconductor shares. Investors were also looking ahead to earnings from memory... Full story

Yahoo Finance • 4 months ago

Absci surges on Eli Lilly, private equity investments

[Spot lit piggy bank] PM Images * Absci (ABSI [https://seekingalpha.com/symbol/ABSI]) is up ~20% in premarket trading Monday after announcing $100M in financing from Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) as well as sever... Full story

Yahoo Finance • 4 months ago

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Absci Corporation Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201™ acro... Full story

Yahoo Finance • 4 months ago

Is Absci Corporation (ABSI) A Good Stock To Buy Now?

Is ABSI a good stock to buy? We came across a bullish thesis on Absci Corporation on TradersPro's Substack. In this article, we will summarize the bulls' thesis on ABSI. Absci Corporation's share was trading at $7.27 as of June 15th.Ocugen... Full story

Yahoo Finance • 4 months ago

Leerink Starts Coverage on Absci Corporation (ABSI)

Absci Corporation (NASDAQ:ABSI) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 4, Leerink initiated coverage on Absci Corporation (NASDAQ:ABSI) with an Outperform rating and a $12 price target. The analyst stat... Full story

Yahoo Finance • 4 months ago

Thursday's ETF Movers: ARKG, TRFK

In trading on Thursday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 7.5% on the day. Components of that ETF showing particular strength include shares of Absci, up about 15.6% and shares of Butterfly Network, up a... Full story

Yahoo Finance • 5 months ago

The 1 AI Stock I'd Put in a Time Capsule and Open in 2036

Key Points Absci uses generative AI to design protein drugs before they are tested in a lab. Partnerships with Merck and Owkin validate Absci's hybrid AI-wet-lab drug platform. Long-term upside with this ticker depends on clinical success... Full story